Pfizer Inc (PFE)

$26.33 -0.37 (-1.39%)
Market Cap 151.82B
Revenue (ttm) 62.58B
Net Income (ttm) 7.77B
EPS (ttm) N/A
PE Ratio 8.13
Forward PE 8.81
Profit Margin 12.42%
Debt to Equity Ratio 0.75
Volume 29,318,700
Avg Vol 37,770,449
Day's Range N/A - N/A
Shares Out 5.69B
Stochastic %K 9%
Beta 0.43
Analysts Sell
Price Target $29.09

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
SpaceXStonks
SpaceXStonks May. 2 at 7:45 AM
$PFE Large pharmaceutical company with stable revenue but slower growth; valuation tied to pipeline and post-pandemic normalization
0 · Reply
TheUnmaker
TheUnmaker May. 2 at 7:23 AM
$TNXP There is a reason we are an uplisted company. Don't be late to the party. Big things to come! $PFE $LLY $PG $JNJ https://www.stocktitan.net/news/TNXP/tonix-pharmaceuticals-announces-uplisting-from-nasdaq-capital-market-ok3to5zr8mfo.html
0 · Reply
TheUnmaker
TheUnmaker May. 2 at 7:19 AM
$TNXP This is the news we need to get our Lymes Diaease vaccine off the ground. This administration is causing a big shift in all industries as long as its meeting their standard. Don't be a skeptic, the Kennedys want this approved. Once we get further down the pipeline with FDA approval, than U believe the campaign to promote this will begin. Lymes Diaease effects alot of people and is a growing issue in the Northeast and Northern states of America. Big things coming. Continue to hold the lines bulls! $PFE $LLY $JNJ $PG https://www.hhs.gov/press-room/secretary-kennedy-convenes-lyme-disease-patients-providers-announce-new-diagnostic-efforts.htm
0 · Reply
Biostock
Biostock May. 2 at 2:12 AM
$SGMT has a first-line acne drug with a potential TAM exceeding $1 billion annually and holds global rights excluding China. Despite this, its market capitalization is only about half of the projected yearly sales. In contrast, $CELC has a second-line cancer drug partnered with $PFE , with a possible TAM under $2.5 billion, yet its market cap exceeds $6 billion. $QQQ $SPY
0 · Reply
DragonAlgo
DragonAlgo May. 2 at 2:07 AM
🐉 $PFE PUT — DragonAlgo® Signal Contract: PFE PUT Expiry: 2026-05-08 | Strike: $26.50 | Type: PUT Option Plan (premium): Entry: $0.77 Stop: $0.55 TP1: $1.00 TP2: $1.31 TP3: $1.85 🔗 https://dragonalgo.com
0 · Reply
scotttrader213
scotttrader213 May. 2 at 1:43 AM
$PFE one day, I hope to see a a drug company with an excellent pipeline, heading more into oncology, actually be in the 45-50 range, the dividend, does help..
0 · Reply
topstockalerts
topstockalerts May. 1 at 11:35 PM
Arvinas shares surged after trading resumed on Friday following the U.S. FDA’s approval of VEPPANU (vepdegestrant), a drug developed in partnership with Pfizer, for patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer who have already progressed after at least one line of endocrine therapy. The approval is a major milestone because VEPPANU becomes the first-ever PROTAC (proteolysis-targeting chimera) therapy authorized by the FDA. This class of drugs works by degrading disease-causing proteins rather than just blocking them, representing a new approach in targeted cancer treatment. According to Arvinas and Pfizer, the decision also came earlier than expected, being granted ahead of the formal PDUFA action date of June 5, 2026, signaling strong regulatory confidence in the treatment’s safety and efficacy profile. $ARVN $PFE
0 · Reply
amrsamir
amrsamir May. 1 at 10:41 PM
$PFE I found this article for you: - https://www.investing.com/news/stock-market-news/us-fda-approves-pfizer-arvinas-breast-cancer-drug-4654649
0 · Reply
TheUnmaker
TheUnmaker May. 1 at 10:32 PM
$TNXP $PFE $PG $JNJ $LLY
0 · Reply
TheUnmaker
TheUnmaker May. 1 at 10:14 PM
$TNXP "Wall Street analysts forecast TNXP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TNXP is 55.42 USD with a low forecast of 34.34 USD and a high forecast of 68.25 USD." https://www.alphaspread.com/security/nasdaq/tnxp/analyst-estimates $PFE $LLY $PG $JNJ
1 · Reply
Latest News on PFE
US FDA approves Pfizer, Arvinas' breast cancer drug

May 1, 2026, 12:37 PM EDT - 15 hours ago

US FDA approves Pfizer, Arvinas' breast cancer drug

ARVN

Pfizer's blood cancer drug meets main goal in late-stage trial

Apr 29, 2026, 7:42 AM EDT - 2 days ago

Pfizer's blood cancer drug meets main goal in late-stage trial

Pfizer's ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma

Apr 29, 2026, 6:45 AM EDT - 2 days ago

Pfizer's ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma

Pfizer Stock Is Declining Today: What's Happening?

Apr 28, 2026, 1:23 PM EDT - 3 days ago

Pfizer Stock Is Declining Today: What's Happening?

Pfizer secures deals to keep heart drug free of generic rivals until 2031

Apr 28, 2026, 10:41 AM EDT - 3 days ago

Pfizer secures deals to keep heart drug free of generic rivals until 2031

Pfizer Reaches Three Settlement Agreements for VYNDAMAX

Apr 28, 2026, 10:17 AM EDT - 3 days ago

Pfizer Reaches Three Settlement Agreements for VYNDAMAX

Bristol Myers, Pfizer to offer blockbuster blood thinner through Mark Cuban's online pharmacy

Apr 24, 2026, 8:36 AM EDT - 7 days ago

Bristol Myers, Pfizer to offer blockbuster blood thinner through Mark Cuban's online pharmacy

BMY

Pfizer Declares Second-Quarter 2026 Dividend

Apr 22, 2026, 4:45 PM EDT - 9 days ago

Pfizer Declares Second-Quarter 2026 Dividend

Pfizer GLP-1 weight loss drug available for pre-order in China

Apr 22, 2026, 5:18 AM EDT - 9 days ago

Pfizer GLP-1 weight loss drug available for pre-order in China

Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026

Apr 21, 2026, 11:51 AM EDT - 10 days ago

Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026

Pfizer's Strategy and Innovation Officer Andrew Baum to leave drugmaker, analyst note says

Apr 20, 2026, 3:05 PM EDT - 11 days ago

Pfizer's Strategy and Innovation Officer Andrew Baum to leave drugmaker, analyst note says

U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Apr 20, 2026, 6:45 AM EDT - 11 days ago

U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

The Big 3: PFE, V, SYF

Apr 16, 2026, 1:01 PM EDT - 15 days ago

The Big 3: PFE, V, SYF

SYF V

Big Pharma Is Turning to China for the Newest Drug Ideas

Apr 10, 2026, 11:00 PM EDT - 21 days ago

Big Pharma Is Turning to China for the Newest Drug Ideas

Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders

Apr 9, 2026, 10:00 AM EDT - 22 days ago

Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders

Why Is Pfizer Stock Dropping Tuesday?

Apr 7, 2026, 1:54 PM EDT - 24 days ago

Why Is Pfizer Stock Dropping Tuesday?

Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs

Apr 2, 2026, 11:14 AM EDT - 4 weeks ago

Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs

NVO LLY

Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

Apr 1, 2026, 11:39 AM EDT - 4 weeks ago

Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

BNTX

Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID vaccines

Apr 1, 2026, 10:13 AM EDT - 4 weeks ago

Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID vaccines

Pharma Offers Defensive Plays in an Uncertain Market. Charts Say Buy These 2 Stocks.

Mar 30, 2026, 10:44 AM EDT - 4 weeks ago

Pharma Offers Defensive Plays in an Uncertain Market. Charts Say Buy These 2 Stocks.

GSK LLY NVO PPH

Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts

Mar 24, 2026, 10:00 AM EDT - 5 weeks ago

Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts

An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive

Mar 23, 2026, 12:46 PM EDT - 5 weeks ago

An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive

VALN

Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive

Mar 23, 2026, 10:35 AM EDT - 5 weeks ago

Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive

VALN

Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss

Mar 23, 2026, 9:36 AM EDT - 5 weeks ago

Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss

VALN

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial

Mar 23, 2026, 7:07 AM EDT - 5 weeks ago

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial

VALN

Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial

Mar 23, 2026, 7:02 AM EDT - 5 weeks ago

Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial

VALN

Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial

Mar 23, 2026, 6:47 AM EDT - 5 weeks ago

Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial

VALN

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

Mar 23, 2026, 6:45 AM EDT - 5 weeks ago

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

VALN

5 ‘Healthy' Dividends Paying Up To 14.1%

Mar 22, 2026, 9:45 AM EDT - 5 weeks ago

5 ‘Healthy' Dividends Paying Up To 14.1%

ARE BME DOC HQH

Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

Mar 20, 2026, 4:30 PM EDT - 6 weeks ago

Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer

Mar 19, 2026, 6:45 AM EDT - 6 weeks ago

TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 6 weeks ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK JNJ

Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial

Mar 17, 2026, 7:49 AM EDT - 6 weeks ago

Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

Mar 17, 2026, 6:45 AM EDT - 6 weeks ago

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study

Mar 9, 2026, 7:27 AM EDT - 7 weeks ago

Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study

Pfizer's Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis

Mar 9, 2026, 6:45 AM EDT - 7 weeks ago

Pfizer's Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis

China approves Pfizer GLP-1 drug for weight management

Mar 6, 2026, 12:40 AM EST - 2 months ago

China approves Pfizer GLP-1 drug for weight management

Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund

Mar 5, 2026, 4:48 PM EST - 2 months ago

Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund

NYSE Content Update: Alysa Liu Rings NYSE Bell After Winning Two Gold Medals

Mar 4, 2026, 8:55 AM EST - 2 months ago

NYSE Content Update: Alysa Liu Rings NYSE Bell After Winning Two Gold Medals

SMWB

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

Mar 3, 2026, 8:10 AM EST - 2 months ago

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

PRGO XRAY

Pfizer CEO flags issues with FDA's vaccine leadership

Mar 2, 2026, 11:14 AM EST - 2 months ago

Pfizer CEO flags issues with FDA's vaccine leadership

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

Feb 27, 2026, 10:00 AM EST - 2 months ago

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

U.S. FDA Grants Full Approval to Pfizer's BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

Feb 24, 2026, 2:29 PM EST - 2 months ago

U.S. FDA Grants Full Approval to Pfizer's BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

Pfizer Adds Sciwind As China Partner For New Weight Loss Drug

Feb 24, 2026, 7:45 AM EST - 2 months ago

Pfizer Adds Sciwind As China Partner For New Weight Loss Drug

Pfizer in diabetes drug deal with Sciwind Biosciences

Feb 23, 2026, 10:26 PM EST - 2 months ago

Pfizer in diabetes drug deal with Sciwind Biosciences

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

Feb 23, 2026, 3:15 PM EST - 2 months ago

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

MRK MRNA

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Feb 23, 2026, 10:00 AM EST - 2 months ago

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Is There 25% Downside For Pfizer Stock?

Feb 18, 2026, 12:00 PM EST - 2 months ago

Is There 25% Downside For Pfizer Stock?

Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer

Feb 17, 2026, 6:45 AM EST - 2 months ago

Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer

Prices, pipelines and patent cliffs: Inside pharma's big reset

Feb 13, 2026, 6:13 AM EST - 2 months ago

Prices, pipelines and patent cliffs: Inside pharma's big reset

AMGN LLY NVO

SpaceXStonks
SpaceXStonks May. 2 at 7:45 AM
$PFE Large pharmaceutical company with stable revenue but slower growth; valuation tied to pipeline and post-pandemic normalization
0 · Reply
TheUnmaker
TheUnmaker May. 2 at 7:23 AM
$TNXP There is a reason we are an uplisted company. Don't be late to the party. Big things to come! $PFE $LLY $PG $JNJ https://www.stocktitan.net/news/TNXP/tonix-pharmaceuticals-announces-uplisting-from-nasdaq-capital-market-ok3to5zr8mfo.html
0 · Reply
TheUnmaker
TheUnmaker May. 2 at 7:19 AM
$TNXP This is the news we need to get our Lymes Diaease vaccine off the ground. This administration is causing a big shift in all industries as long as its meeting their standard. Don't be a skeptic, the Kennedys want this approved. Once we get further down the pipeline with FDA approval, than U believe the campaign to promote this will begin. Lymes Diaease effects alot of people and is a growing issue in the Northeast and Northern states of America. Big things coming. Continue to hold the lines bulls! $PFE $LLY $JNJ $PG https://www.hhs.gov/press-room/secretary-kennedy-convenes-lyme-disease-patients-providers-announce-new-diagnostic-efforts.htm
0 · Reply
Biostock
Biostock May. 2 at 2:12 AM
$SGMT has a first-line acne drug with a potential TAM exceeding $1 billion annually and holds global rights excluding China. Despite this, its market capitalization is only about half of the projected yearly sales. In contrast, $CELC has a second-line cancer drug partnered with $PFE , with a possible TAM under $2.5 billion, yet its market cap exceeds $6 billion. $QQQ $SPY
0 · Reply
DragonAlgo
DragonAlgo May. 2 at 2:07 AM
🐉 $PFE PUT — DragonAlgo® Signal Contract: PFE PUT Expiry: 2026-05-08 | Strike: $26.50 | Type: PUT Option Plan (premium): Entry: $0.77 Stop: $0.55 TP1: $1.00 TP2: $1.31 TP3: $1.85 🔗 https://dragonalgo.com
0 · Reply
scotttrader213
scotttrader213 May. 2 at 1:43 AM
$PFE one day, I hope to see a a drug company with an excellent pipeline, heading more into oncology, actually be in the 45-50 range, the dividend, does help..
0 · Reply
topstockalerts
topstockalerts May. 1 at 11:35 PM
Arvinas shares surged after trading resumed on Friday following the U.S. FDA’s approval of VEPPANU (vepdegestrant), a drug developed in partnership with Pfizer, for patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer who have already progressed after at least one line of endocrine therapy. The approval is a major milestone because VEPPANU becomes the first-ever PROTAC (proteolysis-targeting chimera) therapy authorized by the FDA. This class of drugs works by degrading disease-causing proteins rather than just blocking them, representing a new approach in targeted cancer treatment. According to Arvinas and Pfizer, the decision also came earlier than expected, being granted ahead of the formal PDUFA action date of June 5, 2026, signaling strong regulatory confidence in the treatment’s safety and efficacy profile. $ARVN $PFE
0 · Reply
amrsamir
amrsamir May. 1 at 10:41 PM
$PFE I found this article for you: - https://www.investing.com/news/stock-market-news/us-fda-approves-pfizer-arvinas-breast-cancer-drug-4654649
0 · Reply
TheUnmaker
TheUnmaker May. 1 at 10:32 PM
$TNXP $PFE $PG $JNJ $LLY
0 · Reply
TheUnmaker
TheUnmaker May. 1 at 10:14 PM
$TNXP "Wall Street analysts forecast TNXP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TNXP is 55.42 USD with a low forecast of 34.34 USD and a high forecast of 68.25 USD." https://www.alphaspread.com/security/nasdaq/tnxp/analyst-estimates $PFE $LLY $PG $JNJ
1 · Reply
UsingAGodAlgorithm
UsingAGodAlgorithm May. 1 at 10:07 PM
$SE (-75% from short entry) We are the best on ST as far as we have seen. Check our profile. We also covered these names . $DE $ARM $PFE $NVO
0 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 May. 1 at 7:57 PM
$PFE and $BMY, chart twinsies!
1 · Reply
Micheal_Pothead
Micheal_Pothead May. 1 at 7:53 PM
$PFE 1/2 average daily volume 🎉🎉🎉
0 · Reply
Micheal_Pothead
Micheal_Pothead May. 1 at 7:47 PM
$PFE what a dog
0 · Reply
JFDI
JFDI May. 1 at 7:25 PM
Gabbard going after Fauci, about time $MRNA $PFE
1 · Reply
Willieberich
Willieberich May. 1 at 7:06 PM
$PFE Dded earlier. No Brainer
0 · Reply
pasuny
pasuny May. 1 at 6:32 PM
$PFE This company is cursed because they're selling evil drugs to innocent people. Very dirty and filthy, smells very bad just like fermented Napa cabbage aka kimchi.
0 · Reply
reyofhope
reyofhope May. 1 at 6:19 PM
$PFE this trades like a savings account .
2 · Reply
StocktwitsNews
StocktwitsNews May. 1 at 5:44 PM
ARVN Stock Jumps 10% After FDA Approves Breast Cancer Drug A Month Ahead Of Schedule $ARVN $PFE https://stocktwits.com/news/equity/markets/arvn-stock-gains-fda-approval-breast-cancer-drug-pfizer/cZQVgmpReen
0 · Reply
stockjusthave
stockjusthave May. 1 at 5:34 PM
$PFE How many approvals, how many pipelines, how many years same price. Is this a stock or secured bond Pfizer, Arvinas breast cancer therapy approved by the FDA May 01, 2026, 1:21 PM ETPfizer Inc. (PFE) Stock, ARVN StockGHBy: Dulan Lokuwithana, SA News Editor The U.S. Food and Drug Administration on Friday approved vepdegestrant, a breast cancer therapy developed by Pfizer (PFE) and Arvinas (ARVN) under the brand name Veppanu.
0 · Reply
Micheal_Pothead
Micheal_Pothead May. 1 at 5:04 PM
$PFE fantastic news, LLY is green
1 · Reply
notreload_ai
notreload_ai May. 1 at 4:58 PM
FDA approved $PFE $ARVN Veppanu pill for advanced breast cancer with ESR1 mutation, helping hormone-resistant cases. https://notreload.xyz/xy/fda-approves-veppanu-first-protac-for-esr1-breast-cancer/
0 · Reply